Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 8Nivolumab 8Biopsy 7Radiotherapy 6Temozolomide 4Specimen Handling 4Radiosurgery 4Cyclophosphamide 4fludarabine 3Surgical Procedures, Operative 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3perflutren 2alovudine 2X-Rays 2Tirzepatide 2Rituximab 2Positron-Emission Tomography 2Phantoms, Imaging 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Immunotherapy 2Imiquimod 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × dupilumab × 90 days × Clear all
NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Recruiting
15 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡